Rebecca Siegel

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Cooley advised Printify, a technology platform headquartered in Latvia that makes it possible for anyone, anywhere, to sell customized products with zero upfront investment, on its merger with Printful, a Latvia-based technology company that helps ecommerce sellers of all sizes use production-on-demand and other fulfillment solutions to turn their ideas into brands and products.

Cooley advised LegalZoom, a leading online platform for business formation, on its upsized follow-on public offering at $161 million.

Cooley advised Olema Pharmaceuticals, Inc. on its private placement of approximately $130 million in common stock and a senior secured credit facility with an aggregate principal amount of up to $50 million.  Jodie Bourdet and Julia Boesch led the team advising on the private placement, which included Julia Gage and Rebecca Siegel.  Addison Pierce led the team advising on the credit facility, which included Margaret Barreto.  Olema, whose securities trade on the Nasdaq Global Market under the symbol “OLMA,” is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.